Neurogene Inc. (NGNE)
Nasdaq · Healthcare · Biotechnology
$26.47+3.20%as of Oct 6, 2026, 1:35 AM ET
- Market cap
- $530M
- 52-week range
- $15.93 – $43.66
- 52-week change
- +9.29%
- EPS (trailing)
- −$5.04
- Next earnings
- Nov 12, 2026
Fiscal year to Dec 2025
- Revenue
- $0K (−100.00%)
- Net income
- −$90.4M
- Diluted EPS
- −$4.24
- Free cash flow
- −$78.4M
From the company’s annual report on SEC EDGAR.
About Neurogene Inc.
Neurogene Inc., a clinical stage biotechnology company, develops genetic medicines for rare neurological diseases. The company's product candidates include NGN-401 that is packaged in an adeno-associated virus 9, which is in Phase 1/2 clinical trial for the treatment of Rett syndrome; and NGN-101, a conventional gene therapy candidate that is in Phase 1/2 clinical trial to treat CLN5 Batten disease. It has a license agreement with The University of Edinburgh, Virovek, Inc., Sigma-Aldrich Co. LLC., and Leland Stanford Junior University. The company was founded in 2018 and is headquartered in New York, New York.
Headquarters: New York, United States · 131 employees · neurogene.com